Kuangyn Yen | Gene Regulation and Epigenetics | Best Researcher Award

Posted on by PencisLeave a Comment on Kuangyn Yen | Gene Regulation and Epigenetics | Best Researcher Award

Dr. Kuangyn Yen | Gene Regulation and Epigenetics | Best Researcher Award

Chinese Academy of Medical Sciences and Peking Union Medical College | ChinaĀ 

Author Profile

ScopusĀ 

Orcid ID

šŸ“˜ KUANGYU YEN, PhD: PIONEER IN TRANSCRIPTION REGULATION AND CHROMATIN DYNAMICS

šŸŽ“ EARLY ACADEMIC PURSUITS

Kuangyu Yen's academic journey began at National Taiwan University, where he earned a Bachelor of Science in Horticulture (Molecular Biology Unit) in 1998. His passion for molecular biology led him to pursue advanced degrees at the University of Manchester, UK, where he completed both an MRes (2001) and a Ph.D. in Molecular Biology (2005). His doctoral research laid the foundation for his expertise in transcription regulation, setting the stage for his future research endeavors.

šŸ’¼ PROFESSIONAL ENDEAVORS

Dr. Yen's professional career is marked by a blend of international experiences and prestigious appointments:

  • Chinese Academy of Medical Sciences & Peking Union Medical College (2022-present): Researcher.
  • Southern Medical University (2014-2022): Professor, where he contributed significantly to the academic and research community in Guangzhou, China.
  • Pennsylvania State University (2008-2014): Post-doctoral fellow and later Research Assistant Professor, expanding his expertise in transcription regulation and chromatin dynamics.
  • University of Washington (2005-2007): Post-doctoral fellow, further deepening his understanding of molecular biology at the intersection of chromatin and transcription.
  • National Taiwan University (1998-2000): Research Assistant, where his scientific curiosity began to flourish.

šŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS ON GENE REGULATION AND EPIGENETICS

Dr. Yen's research focus is on transcription regulation and its influence on cell fate determination, particularly through chromatin dynamics. His innovative use of bioinformatic tools, CRISPR/Cas9-engineered depletion, and biochemical reconstitution has made him a leader in understanding how chromatin regulates transcription in a spatiotemporal manner. His research has significant implications for disease diagnosis and treatment, especially in preventing precancerous cells from progressing into cancer cells.Ā One of his notable contributions is the development of a two-tipping point model, which helps explain how cell fate transitions. This model has potential applications in both basic research and clinical practice, offering insights into the molecular mechanisms of various diseases.

šŸŒ IMPACT AND INFLUENCE

Dr. Yenā€™s work has been internationally recognized, and he has secured multiple high-profile grants and awards, such as the Thousand Youth Talents Award and the Outstanding Youth Award. His research has attracted funding from the National Natural Science Foundation of China, the National Key Research and Development Program of China, and international collaborations such as the France-China Joint Research Projects Program. His influence extends to key speaking engagements and workshops in the field of epigenetics and hematopoiesis at global institutions, including John Hopkins University.

šŸ“Š ACADEMIC CITATIONS

With several publications to his name, Dr. Yenā€™s work is well-cited in the scientific community, reinforcing his status as an influential researcher in molecular biology. His contributions to understanding transcription regulation and chromatin dynamics continue to resonate, particularly in the areas of epigenetics and hematopoiesis.

šŸŒŸ LEGACY AND FUTURE CONTRIBUTIONS

Kuangyu Yenā€™s legacy will likely center on his pioneering research into how chromatin structure affects transcriptional regulation and cell fate transitions. His use of cutting-edge tools like CRISPR/Cas9 and bioinformatics has laid the groundwork for future advancements in cancer prevention and molecular diagnostics.Ā Moving forward, Dr. Yenā€™s ongoing research at the Chinese Academy of Medical Sciences is poised to further influence how scientists understand and manipulate transcription regulation. His editorial role at Communication Biology (2024-2026) and other professional activities suggest that his contributions to the field are far from over.

šŸš€ AWARDS AND PROFESSIONAL RECOGNITION

  • National Natural Science Foundation of China: Multiple grants for outstanding research, totaling over 500,000 USD.
  • Thousand Youth Talents Award: A prestigious recognition with funding of 0.67 million USD.
  • Numerous invited talks at top-tier institutions and international conferences.

Kuangyu Yenā€™s continuous dedication to his research and the academic community positions him as a transformative figure in molecular biology, with future contributions set to further shape the field.

šŸ“… FUTURE HIGHLIGHTS

Dr. Yenā€™s ongoing projects and his active engagement with the scientific community, including participation in international editorial boards and professional panels, indicate that his work will continue to shape the future of molecular biology research for years to come.

šŸ“‘NOTABLE PUBLICATIONSĀ 

"RUNX1 Upregulates CENPE to Promote Leukemic Cell Proliferation"Ā 

  • Authors: Liu, S., Yang, J., Sun, G., Yen, K., & Lu, T. (2021).
  • Journal: Molecular Biosciences
  • Year: 2021

"Chemical screening reveals Ronidazole is a superior prodrug to Metronidazole for nitroreductase-induced cell ablation system in zebrafish larvae"Ā 

  • Authors: Lai, S., Kumari, A., Liu, J., Yen, K., & Xu, J.
  • Journal: Genetics and Genomics
  • Year: 2021

"Comprehensive understanding of Tn5 insertion preference improves transcription regulatory element identification"

  • Authors: Zhang, H., Lu, T., Liu, S., Chen, F., & Yen, K.
  • Journal: NAR Genomics and Bioinformatics
  • Year: 2021

"Functional Verification of Novel ELMO1 Variants by Live Imaging in Zebrafish"

  • Authors: Xue, R., Wang, Y., Wang, T., Liu, Q., & Xu, J.
  • Journal: Frontiers in Cell and Developmental Biology
  • Year: 2021

"SPI1-KLF1/LYL1 axis regulates lineage commitment during endothelial-to-hematopoietic transition from human pluripotent stem cells"

  • Authors: Qu, K., Mo, S., Huang, J., Shen, J., & Yen, K.
  • Journal: iScience
  • Year: 2024

Paritha Arumugam | Gene Therapy | Best Researcher Award

Posted on by PencisLeave a Comment on Paritha Arumugam | Gene Therapy | Best Researcher Award

Dr. Paritha Arumugam | Gene Therapy | Best Researcher Award

Cincinnati Children's Hospital Medical Center | United States

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Paritha Arumugam's academic journey began at the University of Madras, Bharathi Women's College, where she earned her B.Sc. in Biochemistry in 1991. She continued her education at the University of Madras, Guindy Campus, obtaining her M.Sc. in Biochemistry in 1993, M.Phil. in Biochemistry in 1994, and Ph.D. in Biochemistry in 1998 under the mentorship of Shyamala Devi, C.S. Her academic excellence was recognized with numerous awards, including the Gold Medal for securing the first rank in her M.Sc. program and various other prestigious prizes from the University of Madras.

PROFESSIONAL ENDEAVORS

Dr. Arumugam's professional career is marked by significant roles in both academic and research settings. She served as a Postdoctoral Research Fellow at the Childrenā€™s Hospital Los Angeles (CHLA) from 2004 to 2006, under the guidance of Dr. Punam Malik in the Division of Hematology-Oncology. She later earned an M.S. in Drug Development from the University of Cincinnati in 2011, where she was advised by Kevin L. Skare.Ā Her academic appointments at the University of Cincinnati College of Medicine and Cincinnati Childrenā€™s Hospital Medical Center (CCHMC) have been pivotal. She progressed from Research Instructor in Pediatrics (2015-2019) to her current position as an Assistant Professor in Pediatrics at the Translational Pulmonary Science Center, Division of Pulmonary Biology, beginning in October 2019.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE THERAPY

Dr. Arumugam's research has significantly advanced the fields of biochemistry and molecular biology, with a particular focus on translational pulmonary science. Her work on developing a novel cell transplantation therapy, specifically Pulmonary Macrophage Transplantation, earned her a plenary talk at the NHLBI Celebration of 15 Years of Basic and Translational Progenitor Cell Research in 2023. Her research has garnered numerous awards, including the Excellence in Hemoglobinopathy Research Award from the National Institutes of Health and multiple abstract and travel awards from the American Society of Hematology.

IMPACT AND INFLUENCE

Dr. Arumugam's impact extends beyond her direct research contributions. Her role in advancing clinical practices is underscored by her licensing and certification in Good Clinical Practice for clinical trials involving drugs and devices. Her expertise in conducting investigator-initiated studies according to FDA regulations and GCP has positioned her as a leader in the field, capable of managing investigational agents and overseeing the ethical conduct of clinical trials.

ACADEMIC CITES

Dr. Arumugam's academic excellence has been recognized with several citations and awards throughout her career. Notably, she has been a recipient of the Cincinnati Childrenā€™s Innovation Excellence Award in 2023 and the NHLBI Celebration of 15 Years of Basic and Translational Progenitor Cell Research Poster Award. Her scholarly contributions are also highlighted by her selection as a Translational Sickle Scholar by the National Institutes of Health.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Arumugam's legacy is defined by her dedication to advancing medical science and improving clinical practices. Her pioneering research on pulmonary macrophage transplantation and her contributions to hemoglobinopathy research underscore her commitment to translational science. Looking forward, Dr. Arumugam aims to continue her impactful research, mentor the next generation of scientists, and contribute to significant advancements in pediatric pulmonary biology and therapeutic developments.

NOTABLE PUBLICATIONS

Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia 2020(52)

FOXM1 nuclear transcription factor translocates into mitochondria and inhibits oxidative phosphorylation 2020(28)

Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment 2021(27)

Role of GM-CSF in regulating metabolism and mitochondrial functions critical to macrophage proliferation 2022(26)

A murine model of hereditary pulmonary alveolar proteinosis caused by homozygous Csf2ra gene disruption 2022(8)

Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Posted on by PencisLeave a Comment on Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Prof Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Cincinnati Children's Hospital Medical Center | United States

Author Profile

Scopus

Early Academic Pursuits

Qing Richard Lu embarked on his academic journey with a Bachelor of Science in Biochemistry from Peking Normal University in Beijing, China, which he completed in 1988. Following this, he pursued a Master of Science in Biophysics at Rutgers University, New Jersey, USA, completing his degree in 1993. He continued his studies at Rutgers University, earning a Ph.D. in Biochemistry in 1997 under the mentorship of Dr. Masayori Inouye.

Professional Endeavors

Dr. Lu's professional career began with a postdoctoral fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, from 1997 to 2002. He worked with Dr. Chuck D. Stiles and collaborated with Dr. David Rowitch. In 2002, he joined the UT Southwestern Medical Center as an Assistant Professor in the Department of Developmental Biology, where he held the position of Southwestern Medical Foundation Endowed Scholar in Medical Research. He was promoted to Associate Professor with tenure in 2009 and continued in this role until 2013.Ā In 2013, Dr. Lu joined Cincinnati Childrenā€™s Hospital Medical Center and the University of Cincinnati College of Medicine. He currently holds the position of Professor with tenure in the Department of Pediatrics. Additionally, he serves as the Scientific Director of the Brain Tumor Center and Program Leader of the Brain Tumor Program in the Division of Experimental Hematology and Cancer Biology, Cancer & Blood Diseases Institute.

Contributions and Research Focus on Neurodegenerative Diseases

Dr. Lu's research primarily focuses on the molecular and cellular mechanisms underlying brain tumors. His work is significant in understanding the biology of brain cancer and developing new therapeutic strategies. He has made notable contributions to the field of experimental hematology and cancer biology through his research on brain tumor development, progression, and treatment.

Impact and Influence

Throughout his career, Dr. Lu has influenced the field of pediatric oncology and neurobiology. His research has provided insights into the genetic and biochemical pathways involved in brain tumors, contributing to the development of novel therapeutic approaches. His work has been recognized through various academic appointments and endowed scholarships, reflecting his significant impact on medical research.

Academic Cites

Dr. Lu's work has been widely published in numerous scientific journals, and his research findings are frequently cited by peers in the field. His publications contribute to the broader scientific understanding of brain tumors and their treatment, solidifying his reputation as a leading expert in the field.

Legacy and Future Contributions

As a leading figure in pediatric oncology and neurobiology, Dr. Lu's legacy is marked by his commitment to advancing scientific knowledge and improving patient outcomes. His ongoing research efforts and leadership roles at Cincinnati Childrenā€™s Hospital Medical Center and the University of Cincinnati College of Medicine continue to shape the future of brain tumor research and treatment. Dr. Luā€™s future contributions are expected to further enhance the understanding and management of brain tumors, paving the way for innovative therapeutic solutions and improved patient care.

Notable PublicationsĀ 

Distinct astrocytic modulatory roles in sensory transmission during sleep, wakefulness, and arousal states in freely moving mice 2023(12)

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability 2023(9)

A road map for the treatment of pediatric diffuse midline glioma 2024(2)

The myelination-associated G protein-coupled receptor 37 is regulated by Zfp488, Nkx2.2, and Sox10 during oligodendrocyte differentiation 2024(1)

BRG1 programs PRC2-complex repression and controls oligodendrocyte differentiation and remyelination 2024